Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Jushi Holdings's Debt-to-Equity or its related term are showing as below:
JUSH'
s Debt-to-Equity Range Over the Past 10 Years
Min: -552.6 Med: 0.54 Max: 30.23
Current: -2.24
During the past 13 years, the highest Debt-to-Equity Ratio of Jushi Holdings was 30.23. The lowest was -552.60. And the median was 0.54.
JUSH's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs JUSH: -2.24
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Jushi Holdings Debt-to-Equity Related Terms
Jushi Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Jushi Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jushi Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jushi Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jushi Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Jushi Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jushi Holdings (JUSH) has a Debt-to-Equity of -2.24 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jushi Holdings and its competitors. According to the industry distribution chart, Jushi Holdings ranks #999999 out of 814 companies in the Drug Manufacturers industry.
Is Jushi Holdings' Debt-to-Equity too high?
Jushi Holdings' current Debt-to-Equity is -2.24. Based on the distribution chart, Jushi Holdings ranks #999999 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jushi Holdings has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jushi Holdings' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jushi Holdings ranks #999999 out of 814 companies for Debt-to-Equity. This places Jushi Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jushi Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jushi Holdings's current Debt-to-Equity is -2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jushi Holdings stock overvalued right now?
Based on GuruFocus' analysis, Jushi Holdings (JUSH) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.62 — trading 23% above its estimated fair value. The current Debt-to-Equity is -2.24. Jushi Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Jushi Holdings (JUSH), the current Debt-to-Equity is -2.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jushi Holdings (JUSH) Overvalued in 2026?
Based on GuruFocus' analysis, Jushi Holdings stock appears to be overvalued.
The current stock price of $0.62 is trading 23% above its estimated GF Value™ of $0.50.
GuruFocus considers Jushi Holdings to be Modestly Overvalued.
Key valuation signals for JUSH:
Debt-to-Equity: -2.24
GF Value™: $0.50 vs. price of $0.62 (23% above fair value)
No single metric tells the full story. See the JUSH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jushi Holdings Inc is a vertically integrated multi-state cannabis and hemp operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. The company operates a diverse portfolio of branded cannabis and hemp-derived assets built upon opportunistic acquisitions, distressed deals, and competitive applications. Its products are offered through brands like Hijinks, The Bank, The Lab, Seche, and Tasteology, among others. The company distributes its products through various retail dispensaries, including Nature's Remedy, Beyond Hello, and NuLeaf, and also operates an e-commerce platform called The Jushi Shop, offering branded apparel, accessories, and other products of its different brands. All of its revenues are generated within the United States.
42GF Score
Get the complete analysis for JUSH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUSH has been successfully added to your 
